209 related articles for article (PubMed ID: 16786043)
21. Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis.
Liu X; Huang G; Zhang J; Zhang L; Liang Z
PLoS One; 2020; 15(10):e0240321. PubMed ID: 33052949
[TBL] [Abstract][Full Text] [Related]
22. Correlation between microRNA expression, clinicopathological characteristics, and prognosis in patients with Non-small cell Lung Cancer: A retrospective study.
Wang X; Zhang Y; Zhi X
Thorac Cancer; 2017 Sep; 8(5):511-516. PubMed ID: 28727276
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Khuri FR; Wu H; Lee JJ; Kemp BL; Lotan R; Lippman SM; Feng L; Hong WK; Xu XC
Clin Cancer Res; 2001 Apr; 7(4):861-7. PubMed ID: 11309334
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
Yang SL; Ren QG; Wen L; Hu JL
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.
Wang X; Zhao H; Lv L; Bao L; Wang X; Han S
Sci Rep; 2016 Jan; 6():19239. PubMed ID: 26754405
[TBL] [Abstract][Full Text] [Related]
26. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
Goulding RE; Chenoweth M; Carter GC; Boye ME; Sheffield KM; John WJ; Leusch MS; Muehlenbein CE; Li L; Jen MH; Rojubally A; Jansen J; Druyts E
Cancer Treat Res Commun; 2020; 24():100200. PubMed ID: 32750661
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer.
Laga AC; Zander DS; Cagle PT
Arch Pathol Lab Med; 2005 Sep; 129(9):1113-7. PubMed ID: 16119982
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of cripto-1 expression in non-small-cell lung cancer patients: a systematic review and meta-analysis.
Wei Y; Jiang J; Wang C; Zou H; Shen X; Jia W; Jin S; Zhang L; Hu J; Yang L; Pang L
Biomark Med; 2020 Mar; 14(4):317-329. PubMed ID: 32134335
[No Abstract] [Full Text] [Related]
29. A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer.
Shen S; Zhang R; Guo Y; Loehrer E; Wei Y; Zhu Y; Yuan Q; Moran S; Fleischer T; Bjaanaes MM; Karlsson A; Planck M; Staaf J; Helland Å; Esteller M; Su L; Chen F; Christiani DC
Mol Oncol; 2018 Jun; 12(6):913-924. PubMed ID: 29656435
[TBL] [Abstract][Full Text] [Related]
30. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.
Steels E; Paesmans M; Berghmans T; Branle F; Lemaitre F; Mascaux C; Meert AP; Vallot F; Lafitte JJ; Sculier JP
Eur Respir J; 2001 Oct; 18(4):705-19. PubMed ID: 11716177
[TBL] [Abstract][Full Text] [Related]
31. Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients.
Molinier O; Goupil F; Debieuvre D; Auliac JB; Jeandeau S; Lacroix S; Martin F; Grivaux M
Respir Med Res; 2020 Mar; 77():46-54. PubMed ID: 32036284
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Zhan P; Qian Q; Yu LK
J Thorac Dis; 2013 Feb; 5(1):40-7. PubMed ID: 23372950
[TBL] [Abstract][Full Text] [Related]
33. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
34. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis.
Meert AP; Paesmans M; Martin B; Delmotte P; Berghmans T; Verdebout JM; Lafitte JJ; Mascaux C; Sculier JP
Br J Cancer; 2002 Sep; 87(7):694-701. PubMed ID: 12232748
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.
Zheng CL; Qiu C; Shen MX; Qu X; Zhang TH; Zhang JH; Du JJ
Asian Pac J Cancer Prev; 2015; 16(5):1881-95. PubMed ID: 25773840
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of estrogen receptors mRNA expression in non-small cell lung cancer: A systematic review and meta-analysis.
Li W; Tse LA; Wang F
Steroids; 2015 Dec; 104():129-36. PubMed ID: 26456481
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis.
Zhang Z; Wang T; Zhang J; Cai X; Pan C; Long Y; Chen J; Zhou C; Yin X
PLoS One; 2014; 9(8):e106053. PubMed ID: 25162713
[TBL] [Abstract][Full Text] [Related]
38. HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.
Brattström D; Wester K; Bergqvist M; Hesselius P; Malmström PU; Nordgren H; Wagenius G; Brodin O
Acta Oncol; 2004; 43(1):80-6. PubMed ID: 15068324
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis.
Su Y; Chen R; Han Z; Xu R; Ma L; Wufuli R; Liu H; Wang F; Ma L; Chen R; Liu J
Pathobiology; 2021; 88(4):267-276. PubMed ID: 34107476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
